Braegger
Fakultäten » Medizinische Fakultät » Kinderspital Zürich: Medizinische Klinik » Gastroenterologie und Ernährung, Abteilung » Prof. Dr. Christian Braegger » Braegger
Current research project
| Title / Titel | Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) | ||||
|---|---|---|---|---|---|
| Abstract (PDF, 14 KB) | |||||
| Summary / Zusammenfassung | Progress accumulated in the understanding of the genetic and immune pathogenesis of IBD, as well as the advent of modern immuno-modulating and biological therapies, have induced profound changes in the management – and possibly in the outcome - of IBD patients. However, there are major gaps in the knowledge needed for clinical decision making, including long-term drug safety of biological therapies, their interactions with older therapies, the relative benefits of the various possible treatment strategies, the chemo-prevention of colon cancer as well as the influence of current treatment options on patient physical, mental and psychosocial long-term state of health. Likewise, information available for global aspects of health care management of these patients is mostly derived from patient populations exposed to treatment strategies that are no longer the standard of care, and the impact of the novel treatment approaches is not established. Based on the development of a population-based cohort in the State of Vaud (cohorte vaudoise), on pre-established criteria for appropriateness of care (EPACT), and taking advantage on the existence of a na-tional network of IBD-oriented laboratories, clinical centres, private practice specialists and social and psychosocial medicine as well as paeditric divisions in the country, the development of a prospective, countrywide cohort is proposed. The clinical and socio-economical data as well as the biological samples to be collected in this cohort aim in particular to analyse appropriateness of care, relations between therapy and patient out-come, impact of disease and therapy on mental health and other psychosocial factors, and economical aspects of patient care. As IBD is a typical model of chronic relapsing inflammatory condition, at least some of the information obtained through this cohort may apply to other conditions like chronic rheuma-tologic diseases or dermatological conditions. At this stage 1102 patients are included, 1065 enrolment data sets are completed, and 308 patients already underwent a first annual follow-up. While some aspects of this project are country-specific, SIBDC is oriented towards international collabo-rations. SIBDC is one of the cohorts included in the EU framework 7 funded IBDase consortium (collabo-ration letter by Dr D. Lottaz previously submitted). SIBDC is one integral part of another project funded by the Crohn’s and Colitis Foundation of America on osteoporosis in young patients (collaboration letter by Pr. S. Ferrari previously submitted). Recently, the European Crohn’s and Colitis Organisation (ECCO) adopted the IBDIS system developed by Pr. W. Reinisch in Vienna as a recommended common data col-lection system within its member scientific communities. We have established contacts with the IBDIS to create a platform able to translate our data in this system. Early feasibility analysis showed a 75% direct homology between the data collection systems, while a further 10-15% of the SIBDC data can be modified to fit the IBNIS database system. Within the project there is a special paediatric cohort that has been setup by the Division of Gastroenterology and Nutrition of the University Children's Hospital Zurich Members of the SIBDC steering committee are: Christoph Beglinger, Prof. Dr. med., Head of the center in Basel, Unispital, Basel Christian Braegger, Prof. Dr. med., Head of the pediatric cohort, Kinderspital, Zürich Philippe De Saussure, Dr.med., Head of local center, Geneva Florian Froehlich, Prof. Dr. med., Head of appropriateness of care project, Priv. pract., Porrentruy and Unispital Basel Roland von Känel, Prof. Dr. med., Head of Psychosocial Health project, Inselspital, Bern Christa Meyenberger, Prof. Dr. med., Head of local center (St Gallen) Pierre Michetti, Prof. Dr. med., PI for the first funding period, Head of the center in Lausanne, now in private practice, Lausanne Christian Mottet, PD Dr. med., Head of scientific committee, Neuchatel Christoph Mueller, Prof. Dr. phil.nat., Head of Biobank, Inselspital, Bern Valérie Pittet, Dr.sc.tech., National cohort coordinator, Lausanne Gerhard Rogler, Prof. Dr. med. Dr. phil., Head of the center in Zürich, University Hospital Zürich Markus Sagmeister, PD Dr. med., Head of Socio-economic project, St Gallen Frank Seibold, Prof. Dr. med., Head of the center in Bern, Inselspital Alex Straumann, Prof. Dr. med., Representative of GI practitioners, Olten John-Paul Vader, Prof. Dr.med., Head of Databank, CHUV, Lausanne Bruno Raffa, Representative of the Crohn & Colitis patient association |
||||
| Publications / Publikationen | Braegger CP, Ballabeni P, Rogler D, Vavrikca S, Friedt M, Pittet V, and the Swiss IBD Cohort Study Group. Epidemiology of IBD - Is there a shift towards onset at a younger age? JPGN 2011;53:141-4.Vavricka S, Spigaglia S, Rogler D, Pittet V, Michetti M, Felley C, Mottet C, Braegger CP, Rogler D, Straumann A, Bauerfeind P, Fried M, Schoepfer A, and the Swiss IBD cohort Study. Systematic evaluation of risk factors for diagnostic delay in Inflammatory Bowel Disease. IBD 2011;000:000-000.Pittet V, Juillerat P, Mottet C, Felley C, Ballabeni P, Burnand B, Michetti P, Vader JP; the Swiss IBD Cohort Study Group (including Braegger CP). Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). Int J Epidemiol 2009;37:1-10Pittet V, Juillerat P, Michetti P, Vader JP, Burnand B, Rogler G, Beglinger C, Seibold F, Mottet C, Felley C, Gonvers JJ, Froehlich F; Swiss IBD Cohort Study Group Group (including Braegger C). Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort. Aliment Pharmacol Ther 2010;32:1007-16Juillerat P, Pittet V, Vader JP, Burnand B, Gonvers JJ, de Saussure P, Mottet C, Seibold F, Rogler G, Sagmeister M, Felley C, Michetti P, Froehlich F; Swiss IBD Cohort Study Group (including Braegger C). Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness. Eur J Gastroenterol Hepatol 2010;22:1352-7Voegtlin M, Vavricka SR, Schoepfer AM, Straumann A, Voegtlin J, Rogler G, Ballabeni P, Pittet V, Buser A, Fried M, Beglinger C; Swiss IBD Cohort Study (including Bragger C). Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals. J Crohns Colitis 2010;4:642-8Eloranta JJ, Wenger C, Mwinyi J, Hiller C, Gubler C, Vavricka SR, Fried M, Kullak-Ublick GA; Swiss IBD Cohort Study Group (including Braegger C). Association of a common vitamin D-binding protein polymorphism with inflammatory bowel disease. Pharmacogenet Genomics 2011;21:559-64.Cámara RJ, Ziegler R, Begré S, Schoepfer AM, von Känel R and the Swiss IBD Cohort Study Group. The Role of Psychological Stress in Inflammatory Bowel Disease: Quality Assessment of Methods of 18 Prospective Studies and Suggestions for Future Research. Digestion 2009 Aug 4; 80(2):129-139. [http://www.ncbi.nlm.nih.gov/pubmed/19657191].Cámara RJ, Begré S, von Känel R. The Effect of Stress-Relieving Interventions on Inflammatory Bowel Disease: Quality Assessment of 10 Therapeutic Studies. Zeitschrift für Psychosomatische Medizin und Psychotherapie; April 2010. [http://www.v-r.de/de/zeitschriften/500028/]. IF=1.149Schoepfer AM, Flogerzi B, Seibold-Schmid B, Schaffer T, Kun JF, Pittet V, Mueller S, Seibold F. Low Mannan-Binding Lectin Serum Levels Are Associated With Complicated Crohn's Disease and Reactivity to Oligomannan (ASCA). Am J Gastroenterol. 2009 Oct;104(10):2508-16. [http://www.ncbi.nlm.nih.gov/pubmed/19532127]. IF=6.012 Schoepfer AM, Schaffer T, Mueller S, Flogerzi B, Vassella E, Seibold-Schmid B, Seibold F. Phenotypic associations of Crohn's disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss Cohort. Inflamm Bowel Dis. 2009 Sep;15(9):1358-67. [http://www.ncbi.nlm.nih.gov/pubmed/19253375]. IF=4.643Pittet V, Juillerat P, Mottet C, Felley C, Ballabeni P, Burnand B, Michetti P, Vader JP; Swiss IBD Cohort Study Group. Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). Int J Epidemiol. 2009 Aug;38(4):922-31. [http://www.ncbi.nlm.nih.gov/pubmed/18782896] . IF=5.262Wojtal KA, Eloranta JJ, Hruz P, Gutmann H, Drewe J, Staumann A, Beglinger C, Fried M, Kullak-Ublick GA, Vavricka SR. Changes in mRNA expression levels of solute carrier transporters in inflammatory bowel disease patients. Drug Metab Dispos. 2009 Sep;37(9):1871-7.[http://www.ncbi.nlm.nih.gov/pubmed/19487253]. IF=3.743Meier Y, Eloranta JJ, Darimont J, Ismair MG, Hiller C, Fried M, Kullak-Ublick GA, Vavricka SR. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos. 2007 Apr;35(4):590-4. [http://www.ncbi.nlm.nih.gov/pubmed/17220238] . IF=3.743Carlson RM, Vavricka SR, Eloranta JJ, Musch MW, Arvans DL, Kles KA, Walsh-Reitz MM, Kullak-Ublick GA, Chang EB. fMLP induces Hsp27 expression, attenuates NF-kappaB activation, and confers intestinal epithelial cell protection. Am J Physiol Gastrointest Liver Physiol. 2007 Apr;292(4):G1070-8. [http://www.ncbi.nlm.nih.gov/pubmed/17185631] . IF=3.258Müller S, Rihs S, Dayer Schneider JM, Paredes BE, Seibold I, Brunner T, Mueller C. Soluble TNF-alpha but not transmembrane TNF-alpha sensitizes T cells for enhanced activationinduced cell death. Eur J Immunol. 2009 Aug 13. [http://www.ncbi.nlm.nih.gov/pubmed/19681056] . IF=5.179Juillerat P, Pittet V, Felley C, Mottet C, Froehlich F, Vader JP, Gonvers JJ, Michetti P. Drug safety in Crohn's disease therapy. Digestion. 2007;76(2):161-8. [http://www.ncbi.nlm.nih.gov/pubmed/18239408] . IF=1.770Mottet C, Juillerat P, Pittet V, Gonvers JJ, Froehlich F, Vader JP, Michetti P, Felley C. Pregnancy and breastfeeding in patients with Crohn's disease. Digestion. 2007;76(2):149-60. [http://www.ncbi.nlm.nih.gov/pubmed/18239407] . IF=1.770Juillerat P, Mottet C, Pittet V, Froehlich F, Felley C, Gonvers JJ, Vader JP, Michetti P. Extraintestinal manifestations of Crohn's disease. Digestion. 2007;76(2):141-8. [http://www.ncbi.nlm.nih.gov/pubmed/18239406] . IF=1.770 Swiss National Science Foundation | 41Mottet C, Juillerat P, Pittet V, Gonvers JJ, Michetti P, Vader JP, Felley C, Froehlich F. Upper gastrointestinal Crohn's disease. Digestion. 2007;76(2):136-40. [http://www.ncbi.nlm.nih.gov/pubmed/18239405] . IF=1.770Froehlich F, Juillerat P, Pittet V, Felley C, Mottet C, Vader JP, Michetti P, Gonvers JJ. Maintenance of surgically induced remission of Crohn's disease. Digestion. 2007;76(2):130-5. [http://www.ncbi.nlm.nih.gov/pubmed/18239404] . IF=1.770Gonvers JJ, Juillerat P, Mottet C, Pittet V, Felley C, Vader JP, Michetti P, Froehlich F. Maintenance of medically induced remission of Crohn's disease. Digestion. 2007;76(2):116-29. [http://www.ncbi.nlm.nih.gov/pubmed/18239403] . IF=1.770Froehlich F, Juillerat P, Mottet C, Pittet V, Felley C, Vader JP, Gonvers JJ, Michetti P. Fibrostenotic Crohn's disease. Digestion. 2007;76(2):113-5. http://www.ncbi.nlm.nih.gov/pubmed/18239402] . IF=1.770Felley C, Mottet C, Juillerat P, Pittet V, Froehlich F, Vader JP, Michetti P, Gonvers JJ. Fistulizing Crohn's disease. Digestion. 2007;76(2):109-12. [http://www.ncbi.nlm.nih.gov/pubmed/18239401] . IF=1.770Michetti P, Mottet C, Juillerat P, Pittet V, Felley C, Vader JP, Gonvers JJ, Froehlich F. Severe and steroid-resistant Crohn's disease. Digestion. 2007;76(2):99-108. [http://www.ncbi.nlm.nih.gov/pubmed/18239400] . IF=1.770Michetti P, Juillerat P, Mottet C, Pittet V, Gonvers JJ, Vader JP, Froehlich F, Felley C. Mild-to-moderate active luminal Crohn's disease. Digestion. 2007;76(2):92-8. [http://www.ncbi.nlm.nih.gov/pubmed/18239399] . IF=1.770Juillerat P, Froehlich F, Felley C, Pittet V, Mottet C, Gonvers JJ, Michetti P, Vader JP. EPACT II: project and methods. Digestion. 2007;76(2):84-91. [http://www.ncbi.nlm.nih.gov/pubmed/18239398] . IF=1.770Guessous I, Juillerat P, Pittet V, Froehlich F, Burnand B, Mottet C, Felley C, Michetti P, Vader JP. Evaluating appropriateness of treatment for Crohn's disease: feasibility of an explicit approach. Digestion. 2007;75(1):46-52. http://www.ncbi.nlm.nih.gov/pubmed/17429207]. IF=1.770Vader JP, Froehlich F, Juillerat P, Burnand B, Felley C, Gonvers JJ, Mottet C, Pittet V, Dubois RW, Wietlisbach V, Michetti P. Appropriate treatment for Crohn's disease: methodology and summary results of a multidisciplinary international expert panel approach--EPACT. Digestion. 2006;73(4):237-48. [http://www.ncbi.nlm.nih.gov/pubmed/16940727] . IF=1.770Juillerat P, Christen-Zäch S, Troillet FX, Gallot-Lavallée S, Pannizzon RG, Michetti P. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review. Dermatology. 2007;215(3):245-51. [http://www.ncbi.nlm.nih.gov/pubmed/17823524] . IF=2.741Juillerat P, Pittet V, Bulliard JL, Guessous I, Antonino AT, Mottet C, Felley C, Vader JP, Michetti P. Prevalence of Inflammatory Bowel Disease in the Canton of Vaud (Switzerland): A population-based cohort study. Journal of Crohn's and Colitis (2008) 2, 131–141. [http://www.ecco-jccjournal.org/]. IF=1.729Pierre Michetti, Marc Stelle, Pascal Juillerat, Miquel Gassull, Franz Josef Heil, Eduard Stange, Christian Mottet, Jean-Jacques Gonvers, Valérie Pittet, John-Paul Vader, Florian Froehlich, Christian Felley. Appropriateness of therapy for active Crohn's disease: Results of a multidisciplinary international expert panel—EPACT II. Journal of Crohn's and Colitis (2009) 3, 232–240. [http://www.ecco-jccjournal.org/]. IF=1.729Christian Felley, John-Paul Vader, Pascal Juillerat, Valérie Pittet, Colm O'Morain, Yves Panis, Boris Vucelic, Jean-Jacques Gonvers, Christian Mottet, Florian Froehlich, Pierre Michetti, the EPACT II Study Group. Appropriate therapy for fistulizing and fibrostenotic Crohn's disease: Swiss National Science Foundation | 42 Results of a multidisciplinary expert panel — EPACT II. Journal of Crohn's and Colitis (2009) 3, 250–256. [http://www.ecco-jccjournal.org/]. IF=1.729Pascal Juillerat John-Paul Vader, Christian Felley, Valérie Pittet, Jean-Jacques Gonvers, Christian Mottet, Willem A. Bemelman, Marc Lémann, Tom Öresland, f, Pierre Michetti, Florian Froehlich and the EPACT II Study Group. Appropriate maintenance treatment for Crohn's disease: Results of a multidisciplinary international expert panel — EPACT II. Journal of Crohn's and Colitis (2009) 3, 241–249. [http://www.ecco-jccjournal.org/]. IF=1.729Christian Mottet, John-Paul Vader, Christian Felley, Florian Froehlich, Jean-Jacques Gonvers, Pascal Juillerat, Reinhold Stockbrügger, Erika Angelucci, Frank Seibold, Pierre Michetti, Valérie Pittet, and the EPACT II Study Group. Appropriate management of special situations in Crohn's disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): Results of a multidisciplinary international expert panel—EPACT II. Journal of Crohn's and Colitis (2009) 3, 257–263. [http://www.ecco-jccjournal.org/].IF=1.729Binda E, Erhart D, Schenk M, Zufferey C, Renzulli P, Mueller C. Quantitative isolation of mouse and human intestinal intraepithelial lymphocytes by elutriation centrifugation. J Immunol Methods. 2009 May 15;344(1):26-34. http://www.ncbi.nlm.nih.gov/pubmed/19278662] . IF=2.347Schenk M, Mueller C. The mucosal immune system at the gastrointestinal barrier. Best Pract Res Clin Gastroenterol. 2008;22(3):391-409.[http://www.ncbi.nlm.nih.gov/pubmed/18492562] . IF=2.480Schenk M, Bouchon A, Seibold F, Mueller C. TREM-1--expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J Clin Invest. 2007 Oct;117(10):3097-106. [http://www.ncbi.nlm.nih.gov/pubmed/17853946] . IF=15.387 32. Ismair MG, Vavricka SR, Kullak-Ublick GA, Fried M, Mengin-Lecreulx D, Girardin SE. hPepT1 selectively transports muramyl dipeptide but not Nod1-activating muramyl peptides. Can J Physiol Pharmacol. 2006 Dec;84(12):1313-9. [http://www.ncbi.nlm.nih.gov/pubmed/17487240] . IF=1.341Frei P, Fried M, Hungerbuhler V, Rammert C, Rousson V, Kullak-Ublick GA. Analysis of risk factors for low bone mineral density in inflammatory bowel disease. Digestion. 2006;73(1):40- 6. [http://www.ncbi.nlm.nih.gov/pubmed/16543736] . IF=1.770Seibold F, Boldt AB, Seibold-Schmid B, Schoepfer AM, Flogerzi B, Müller S, Kun JF. Association of deficiency for mannan-binding lectin with anti-mannan antibodies in Crohn's disease: a family study. Inflamm Bowel Dis. 2007 Sep;13(9):1077-82. [http://www.ncbi.nlm.nih.gov/pubmed/17480019] . IF=4.643Vavricka SR, Burri E, Beglinger C, Degen L, Manz M. Serum protein electrophoresis: an underused but very useful test. Digestion. 2009;79(4):203-10. [http://www.ncbi.nlm.nih.gov/pubmed/19365122] . IF=1.770Vavricka SR, Rogler G. New insights into the pathogenesis of Crohn's disease: are they relevant for therapeutic options? Swiss Med Wkly. 2009 Sep 19;139(37-38):527-34. [http://www.ncbi.nlm.nih.gov/pubmed/19838869] . IF=1.681Vavricka SR, Rogler G. Treatment of severe ulcerative colitis: differences in elderly patients? Dig Dis. 2009;27(3):315-21. [http://www.ncbi.nlm.nih.gov/pubmed/19786758] . IF=1.487Zeitz J, Mullhaupt B, Fruehauf H, Rogler G, Vavricka SR. Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone. Hepatology. 2009 Aug;50(2):653-4. [http://www.ncbi.nlm.nih.gov/pubmed/19575458] . IF=10.840Lee J, Tattoli I, Wojtal KA, Vavricka SR, Philpott DJ, Girardin SE. pH-dependent internalization of muramyl peptides from early endosomes enables Nod1 and Nod2 signaling. J Biol Swiss National Science Foundation | 43 Chem. 2009 Aug 28;284(35):23818-29. [http://www.ncbi.nlm.nih.gov/pubmed/19570976] . IF=5.328Vavricka SR, Rogler G. [Therapy of ulcerative colitis]. [Article in German] Praxis (Bern 1994). 2009 Feb 18;98(4):209-12. [http://www.ncbi.nlm.nih.gov/pubmed/19224489] .Vavricka SR, Rogler G. [Treatment of Crohn's disease]. [Article in German] Praxis (Bern 1994). 2009 Jan 21;98(2):77-81. [http://www.ncbi.nlm.nih.gov/pubmed/19153955] .Manz M, Beglinger C, Vavricka SR. Fatal invasive pulmonary aspergillosis associated with adalimumab therapy. Gut. 2009 Jan;58(1):149. [http://www.ncbi.nlm.nih.gov/pubmed/19091839] .Vavricka SR, Dirnhofer S, Degen L. Polyarteritis nodosa mimicking inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007 Nov;5(11):A22. [http://www.ncbi.nlm.nih.gov/pubmed/17981238] . IF=5.642Vavricka SR, Manz M, Burri E. Trichuris trichiura (whipworm). Clin Gastroenterol Hepatol. 2009 Oct;7(10):A16. [http://www.ncbi.nlm.nih.gov/pubmed/19264573] . IF=5.642Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, Seibold F. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010 Jan;105(1):162-9. [http://www.ncbi.nlm.nih.gov/pubmed/19755969] . IF=6.012Schoepfer AM, Vavricka SR, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Seibold F, Straumann A, Michetti P. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey. Inflamm Bowel Dis 2010. [http://www.ncbi.nlm.nih.gov/pubmed/20014021] . IF=4.643Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: Correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009 May 21;15(12):1851- 1858. [http://www.ncbi.nlm.nih.gov/pubmed/19462421] . IF=4.643Nichita C, Stelle M, Vavricka S, El-Wafa Ali A, Ballabeni P, de Saussure P, Straumann A, Rogler G, Michetti P. Clinical experience with adalimumab in a multicenter swiss cohort of patients with Crohn's disease. Digestion. 2010;81(2):78-85. [http://www.ncbi.nlm.nih.gov/pubmed/20093835] . IF=1.770Eloranta JJ, Hiller C, Häusler S, Stieger B, Kullak-Ublick GA. Vitamin D3 and its nuclear receptor increase the expression and activity of the human proton-coupled folate transporter. Mol Pharmacol 2009; 76: 1062-1071. [http://www.ncbi.nlm.nih.gov/pubmed/19666701] . IF=4.531Schmidt S, Guibal A, Meuwly JY, Michetti P, Felley C, Meuli R, Schnyder P, Denys A. Acute Complications of Crohn’s Disease: Comparison of Multidetector-Row Computed Tomographic Enterography with Magnetic Resonance Enterography. Digestion 2010;82:229–238. [http://www.ncbi.nlm.nih.gov/pubmed/20588038] . IF=1.770Appropriateness of the Initial Treatment for non Complicated Luminal Crohn’s Disease: Application of EPACT Criteria to the EC-IBD European Cohort. Pascal Juillerat, Valerie Pittet, Christian Mottet, Christian Felley, Jean-Jacques Gonvers, John-Paul Vader, Bernard Burnand, Florian Froehlich , Frank L.Wolters, Reinhold W. Stockbruegger, Pierre Michetti and the EC-IBD group. Scand J Gastro. 2010 Jul 26. [http://www.ncbi.nlm.nih.gov/pubmed/20653489]. IF=2.084Vavricka SR, Rogler G. Recent advances in the etiology and treatment of Crohn's disease. Minerva Gastroenterol Dietol. 2010 Jun;56(2):203-11. [http://www.ncbi.nlm.nih.gov/pubmed/20485257].Frequency and Risk Factors for Extraintestinal Manifestations in the Swiss Inflammatory Bowel Disease Cohort. SR Vavricka, L Brun, P Ballabeni, V Pittet, Bettina M Prinz Vavricka, J Swiss National Science Foundation | 44 Zeitz, G Rogler, AM Schoepfer and the Swiss IBD cohort study group. Am J Gastro; in press. IF=6.012Anemia in inflammatory bowel disease: differences between private practice and university hospital: a prospective study. Manuela Voegtlin, Christoph Beglinger, Alex Straumann, Jürg Voegtlin, Gerhard Rogler, Andreas Buser, Pierluigi Ballabeni, Valérie Pittet, Stephan R. Vavricka. Journal of Crohn's and Colitis; in press. IF=1.729Infliximab for Crohn’s disease in the Swiss IBD Cohort Study: Clinical management and appropriateness. Pascal Juillerat, Valérie Pittet, John-Paul Vader, Bernard Burnand, Jean-Jacques Gonvers, Philippe de Saussure, Christian Mottet, Frank Seibold, Gerhard Rogler, Markus Sagmeister, Christian Felley, Pierre Michetti, Florian Froehlich and the Swiss IBD Cohort Study Group. Eur J Gastro; in press. IF=1.662Appropriateness of therapy for fistulizing Crohn’s disease: findings from a nationwide inflammatory bowel disease cohort. Valerie Pittet, Pascal Juillerat, John-Paul Vader, Bernard Burnand, Pierre Michetti, Gerhard Rogler, Christoph Beglinger, Frank Seibold, Christian Mottet, Christian Felley, Jean-Jacques Gonvers, Florian Froehlich and the Swiss IBD Cohort Study Group. Aliment Pharmacol Ther; in press. IF=4.357Effects of social support on the clinical course of Crohn’s disease. Rafael J A Cámara, Paul S Lukas, Valérie Pittet Stefan Begré, Roland von Känel and the Swiss IBD Cohort Study Group. Inflamm Bowel Dis; in press. . IF=4.643 |
||||
| Keywords / Suchbegriffe | Inflammatory bowel disease; Morbus Crohn; Colitis Ulcerosa; Indeterminate Colitis; Cohort, Epidemiology; Population-based study; Multicentric, Appropriateness of care, Cost-effectiveness, Mental health, Psychological stress, Quality of life, Biobank | ||||
| Project leadership and contacts / Projektleitung und Kontakte |
|
||||
| Funding source(s) / Unterstützt durch |
SNF (Personen- und Projektförderung) Funded by the SNF (Personen- und Projektförderung) since 2006, Beitragsnummer 3347C0-108792 |
||||
| In collaboration with / In Zusammenarbeit mit |
|
||||
| Duration of Project / Projektdauer | Jan 2009 to Mar 2014 |